CRON logo

Cronos Group Inc. Stock Price

TSX:CRON Community·CA$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

CRON Share Price Performance

CA$3.99
1.20 (43.01%)
CA$3.45
Fair Value
CA$3.99
1.20 (43.01%)
15.7% overvalued intrinsic discount
CA$3.45
Fair Value
Price CA$3.99
AnalystLowTarget CA$3.45
AnalystConsensusTarget CA$4.68
AnalystHighTarget CA$5.50

CRON Community Narratives

·
Fair Value CA$3.45 15.7% overvalued intrinsic discount

Regulatory Shifts In Israel And Germany Will Hinder Cannabis Growth

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value CA$4.68 14.7% undervalued intrinsic discount

GrowCo Capacity And Global Markets Will Unlock Potential

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
·
Fair Value CA$5.5 27.5% undervalued intrinsic discount

Global Cannabis Legalization Will Expand Wellness And Medicine Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CA$5.5
27.5% undervalued intrinsic discount
Profit Margin
25.64%
Future PE
24.39x
Price in 2029
CA$6.61
CA$3.45
15.7% overvalued intrinsic discount
Profit Margin
35.27%
Future PE
16.21x
Price in 2029
CA$4.15

Trending Discussion

Updated Narratives

CRON logo

CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook

Fair Value: CA$5.5 27.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CRON logo

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Fair Value: CA$4.68 14.7% undervalued intrinsic discount
9 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CRON logo

CRON: Partial Rescheduling Expectations Will Constrain Future Earnings Power

Fair Value: CA$3.45 15.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards

Cronos Group Inc. Key Details

US$159.5m

Revenue

US$96.3m

Cost of Revenue

US$63.2m

Gross Profit

US$65.0m

Other Expenses

-US$1.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.0049
39.61%
-1.14%
0%
View Full Analysis

About CRON

Founded
n/a
Employees
610
CEO
Michael Gorenstein
WebsiteView website
thecronosgroup.com

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Recent CRON News & Updates

Narrative Update Jun 28

CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook

Analysts have raised their Cronos Group price target by CA$0.50 to CA$5.50, citing revised assumptions around higher projected revenue growth, a different discount rate, and updated margin and P/E expectations following recent research commentary and a more favorable view on partial cannabis re scheduling. Analyst Commentary Recent research on Cronos Group highlights how shifting views on cannabis policy and updated valuation work are feeding into more constructive analyst sentiment on the stock.
Narrative Update Jun 14

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.

Recent updates

No updates